Navigation Links
Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
Date:2/28/2008

y disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva Pharmaceuticals BV, is headquartered in Amsterdam, the Netherlands, and its majority-owned subsidiary, Arriva Pharmaceuticals, Inc., is located in Alameda, California. For additional information please visit: http://www.arrivapharm.com

About Nordic Biotech:

Nordic Biotech is a global operating special situations fund family, with about 200 million USD under management. Primary focus is pharmaceutical development companies with late stage clinical programs. Nordic Biotech is based primarily in Copenhagen, Denmark with a presence in Boston and San Francisco. For more information, please visit http://www.NordicBiotech.com.

About MPM:

MPM Capital L.P. is a global investment management firm focused solely on life sciences investing. One of the largest investment management firms dedicated to the life sciences sector, MPM Capital has offices in Boston, San Francisco and New York City. MPM's portfolio ranges from start-ups to large capitalization public companies, with a primary focus on biopharmaceutical and medical device companies nearing commercialization of products or those companies that already offer product-driven opportunities. The firm manages over $2.5 billion in assets through the MPM BioVentures Family of venture capital funds and the MPM BioEquities public market fund. More information on MPM can be found at http://www.MPMCapital.com.


'/>"/>
SOURCE Arriva Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... FREMONT, Calif. , July 7, 2015  The ... and Velos, Inc. have entered into a seven year ... research nationally throughout South Korea and ... signing was accompanied by a two day joint workshop between ... Korea.  National Cancer Center President Dr. Lee ...
(Date:7/7/2015)... , Kalifornien, 7. Juli 2015 /PRNewswire/ ... Medizintechnikunternehmen, das sich der Entwicklung innovativer Geräte ... heute den Zugang von R. Michael ... Herr Kleine verfügt über eine ... Medizintechnik und Gesundheitsfürsorge. Er hat verschiedene globale ...
(Date:7/7/2015)... Md. , July 7, 2015 ... (CRO) focusing in Oncology, Vaccines, and General Medicine ... the final locked database to Heron Therapeutics, Inc. ... 3 receptor antagonist product candidate SUSTOL® (granisetron ... regimen with the IV NK 1 receptor ...
Breaking Medicine Technology:National Cancer Center of South Korea and Velos Sign Long-Term Velos eResearch Agreement 2National Cancer Center of South Korea and Velos Sign Long-Term Velos eResearch Agreement 3Sequent Medical beruft Mike Kleine in den Aufsichtsrat 2Sequent Medical beruft Mike Kleine in den Aufsichtsrat 3Accelovance Completes Trial Enrollment and Delivery of Clinical Data for Heron Therapeutics' Phase 3 Trial 2
... ALTO, Calif., Jan. 10, 2012 Varian Medical Systems (NYSE: ... a new radiotherapy treatment planning tool designed to work with ... the amount of time needed for planning advanced treatments. ... clinician must take the patient,s anatomical images and identify and ...
... Agreement allows development for potential treatment of chronic constipation ... SHPGY ), the global specialty biopharmaceutical company, announced today ... market Resolor ® (prucalopride) in the United States ... of the agreement have not been disclosed. ...
Cached Medicine Technology:Varian Medical Systems Receives FDA 510(k) Clearance for Software that Speeds Up Radiotherapy Treatment Planning 2Shire Acquires US Rights to Resolor(R) (prucalopride) 2Shire Acquires US Rights to Resolor(R) (prucalopride) 3Shire Acquires US Rights to Resolor(R) (prucalopride) 4
(Date:7/7/2015)... ... July 08, 2015 , ... The OR Business Management Conference ... business managers increase efficiency, reduce supply chain costs, optimize throughput, and improve patient ... Phoenix Glendale, February 21-24, 2016. The agenda has been announced and includes four ...
(Date:7/7/2015)... ... 2015 , ... The National Association of Professional Women (NAPW) honors ... Year Circle. She is recognized with this prestigious distinction for leadership in pharmacy. NAPW ... members and over 200 operating Local Chapters. , ā€œIā€™m pleased to recognize Alyssa with ...
(Date:7/7/2015)... ... July 08, 2015 , ... LAGOS, Nigeria ā€“ In ... crafts a poignant, stirring tale about a young woman who deals with abuse, alienation ... Taking place in a poor, superstitious village in Eastern Nigeria and in ...
(Date:7/7/2015)... Angeles, CA (PRWEB) , ... July 07, 2015 ... ... engineer of patented products, announces the IV Tube Holder, a medical invention that ... largest medical device market in the world which will be worth $133 billion ...
(Date:7/7/2015)... ... ... reputable source of authentic tickets for the CONCACAF Gold Cup Group A matches ... Massachusetts. , The second round of matches being held from Group A of the 2015 ... be held on Friday, July 10th and will feature Honduras vs. Panama and the United ...
Breaking Medicine News(10 mins):Health News:Agenda, Pre-Conference Workshop, and More Announced for OR Business Management Conference 2Health News:Agenda, Pre-Conference Workshop, and More Announced for OR Business Management Conference 3Health News:National Association of Professional Women Inducts Dr. Alyssa Greedy, Pharm. D., Pharmacy Manager at Walgreens, Into its VIP Woman of the Year Circle 2Health News:Uju Amanambu crafts poignant tale depicting woes of mental illness 2Health News:Uju Amanambu crafts poignant tale depicting woes of mental illness 3Health News:New Evidence Shows Why Hospital Weekend Effect Is So Dangerous As World Patent Marketing Introduces A New Medical Invention 2Health News:New Evidence Shows Why Hospital Weekend Effect Is So Dangerous As World Patent Marketing Introduces A New Medical Invention 3Health News:New Evidence Shows Why Hospital Weekend Effect Is So Dangerous As World Patent Marketing Introduces A New Medical Invention 4Health News:New Evidence Shows Why Hospital Weekend Effect Is So Dangerous As World Patent Marketing Introduces A New Medical Invention 5Health News:CONCACAF Group A Tickets: USA vs. Haiti & Honduras vs. Panama at Gillette Stadium: Ticket Down Slashes CONCACAF Gold Cup Group A Tickets in Foxborough 2
... more clinical preventive services, dedicate funding source to public ... 11 Partnership for Prevention today unveiled health ... and health promotion efforts to tackle the chronic diseases ... , Under these proposals, federally ...
... Inc. (Nasdaq: PTIE ) has received a Complete Response ... New Drug Application (NDA) for REMOXY(R), an abuse-resistant controlled-release form of ... the NDA is not approved in its present form. ... non-clinical data will be required to support the approval of REMOXY. ...
... touted as the "cure" for health care, but a new ... that implementation of technology and related devices is not a ... safety of patient care. , , ... to understanding when a technology may (or may not) be ...
... Dental Management,Services, Inc. (Nasdaq: BDMS ), operators ... The Company,s board of directors,has declared a quarterly ... stock.,The dividend is payable January 9, 2009, to shareholders ... Birner Dental Management Services, Inc. acquires, develops, ...
... agonists may cause asthma problems and death, agency officials ... of four asthma medications will be weighed by a U.S. ... hearings end Thursday. , The controversy over these drugs has ... recently calling for banning the use of these drugs for ...
... PRA International, a leading,Clinical Research Organization, announces ... Mexico. With years of long-standing South American ... The region,s existing base of clinical,sites with expertise ... to PRA,s therapeutic focus. The expansion is ...
Cached Medicine News:Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 2Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 3Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 2Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 3Health News:Joint Commission Alert: Prevent Technology-Related Health Care Errors 2Health News:Joint Commission Alert: Prevent Technology-Related Health Care Errors 3Health News:FDA Panel Mulls Safety of Asthma Meds 2Health News:FDA Panel Mulls Safety of Asthma Meds 3Health News:PRA International Expands Operations in Mexico 2
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Inverness Medical Professional Diagnostics is a ... extensive IFA and DFA test menu that ... and STDs as well as miscellaneous conjugates ... give you a wide assortment of substrates ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
Medicine Products: